Pharmaceutical composition combining at least two distinct nanoparticles and a pharmaceutical compound, preparation and uses thereof
The present invention relates to a pharmaceutical composition comprising the combination of (i) at least two distinct biocompatible nanoparticles and (ii) at least one compound of interest, typically at least one pharmaceutical compound, to be administered to a subject in need of such at least one compound of interest, wherein the at least two distinct biocompatible nanoparticles potentiate the compound(s) of interest efficiency. The at least two biocompatible nanoparticles can be administered sequentially or simultaneously to the subject but are to be administered separately, typically with an interval of between more than about 5 minutes and about 72 hours, from the at least one compound of interest, preferably before the administration of the at least one compound of interest, to said subject. The longest dimension of the at least two biocompatible nanoparticles is typically between about 4 nm and about 500 nm. The absolute surface charge value of a first biocompatible nanoparticle is of at least |10 mV| and the absolute surface charge value of the second biocompatible nanoparticle, or of any additional biocompatible nanoparticle, has a difference of at least 10 mV with the absolute surface charge value of the first biocompatible nanoparticle.
1. A method for treating cancer comprising a step of administering at least one pharmaceutical anti-cancer compound to a subject in need thereof and a distinct step of administering at least two distinct biocompatible lipid-based nanoparticles to said subject, wherein the longest dimension of each of the at least two biocompatible nanoparticles is between about 4 nm and about 500 nm, the surface charge value of a first biocompatible nanoparticle is a negative charge below −10 mV, the surface charge value of a second biocompatible nanoparticle, or of any additional biocompatible nanoparticle, is negative and has a difference of at least 10 mV to the negative surface charge value of the first biocompatible nanoparticle, each of the at least two biocompatible nanoparticles is not used as the at least, one pharmaceutical compound, and said at least two distinct biocompatible nanoparticles are administered to the subject separately from the at least one pharmaceutical compound between 4 hours and about 24 hours before said at least one pharmaceutical compound.
2. The method according to claim 1 , wherein the at least two distinct biocompatible nanoparticles are to be administered separately in an additional distinct step, or simultaneously, in the subject in need of the pharmaceutical compound.
3. The method according to claim 1 , wherein each of the at least two nanoparticles is further covered with a biocompatible coating.
4. The method according to claim 1 , wherein the administration of the at least two biocompatible nanoparticles and of the at least one pharmaceutical compound maintains the therapeutic benefit of said at least one pharmaceutical compound and reduces toxicity, or increases the therapeutic benefit of said at least one pharmaceutical compound for an equivalent or reduced toxicity, for the subject, when compared to therapeutic benefit and toxicity induced by the standard therapeutic dose(s) of said at least one pharmaceutical compound.
5. The method according to claim 1 , wherein the administration of the at least two biocompatible nanoparticles and of the at least one pharmaceutical compound allows a reduction of at least 10% of the administered at least one pharmaceutical compound therapeutic dose when compared to the standard therapeutic dose of said at least one pharmaceutical compound while maintaining the same therapeutic benefit for an equivalent toxicity or a reduced toxicity for the subject or while increasing the therapeutic benefit for an equivalent or reduced toxicity for the subject.
6. The method according to claim 1 , wherein the at least two nanoparticles are cleared from the subject to whom it has been administered within one hour and six weeks after their administration to said subject.
7. The method according to claim 1 , wherein the at least one pharmaceutical compound is an organic compound selected from a biological compound, a small molecule targeted therapeutic, an oncolytic virus and a cytotoxic compound.
8. The method according to claim 7 , wherein the at least one pharmaceutical compound is selected from an antibody, an oligonucleotide, and a synthesized peptide.
9. The method according to claim 1 , wherein the at least one pharmaceutical compound is an inorganic compound selected from a metallic nanoparticle, a metal oxide nanoparticle, a metal sulfide nanoparticle, and any mixture thereof.
10. The method according to claim 1 , wherein the at least one pharmaceutical compound is encapsulated in, or bound to, a carrier.
11. The method according to claim 1 , wherein the at least two biocompatible nanoparticles are administered separately or simultaneously in a subject in need of the at least one pharmaceutical compound and between about 12 hours to about 24 hours before the pharmaceutical compound.
12. The method according to claim 1 , wherein the at least one pharmaceutical compound is irinotecan.